Using Omega-3 products to improve eczema symptoms
Impact of a Daily Application of Omega-3 Monoglycerides Based Serum and Cream on Self-assessment of Eczema Severity as Well as on the Ratio of 4 Bacteria of the Skin Microbiota (Staphylococcus Aureus, Staphylococcus Epidermis, Cutibacterium Acnes and Streptococcus Pyogenes): Exploratory Study (COS-PBP-02)
This study tests if using Omega-3 cream and serum every day can help improve eczema symptoms in people with the condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 16 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | SCF Pharma Industry-sponsored |
| Locations | 1 site (Rimouski, Quebec) |
| Trial ID | NCT06155513 on ClinicalTrials.gov |
What this trial studies
This exploratory study investigates the effects of daily applications of Omega-3 monoglyceride serum and cream on eczema severity. Sixteen participants will be enrolled and divided into two groups, each receiving different formulations for 42 days. The study aims to assess the prebiotic potential of these topical products and monitor any adverse effects. The baseline condition will serve as a control to evaluate the treatment's effectiveness on the targeted eczema area.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with eczema who have not used corticosteroids in the two weeks prior to the study.
Not a fit: Patients who have used corticosteroids recently or are unable to comply with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel topical treatment option for patients suffering from eczema.
How similar studies have performed: While the use of Omega-3 fatty acids in skin care is recognized, this specific approach using pre-activated Omega-3 monoglycerides is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participant aged of at least 18 years old. 2. Participant diagnosed with eczema who did not use corticosteroids in the 14 days prior to study day 1; 3. Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter. 4. Participant without intellectual problems likely to limit the validity of consent to participate in the study and compliance with protocol requirements, having the ability to cooperate adequately, understand and observe the instructions of research staff. Exclusion Criteria: * None
Where this trial is running
Rimouski, Quebec
- SCF Pharma — Rimouski, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Samuel P Fortin, Ph.D — SCF Pharma
- Study coordinator: Samuel Fortin, Ph.D
- Email: sfortin@scfpharma.com
- Phone: 418-750-8590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.